Literature DB >> 34362224

SARS-CoV-2 and the Brain: What Do We Know about the Causality of 'Cognitive COVID?

Hashir Ali Awan1, Mufaddal Najmuddin Diwan1, Alifiya Aamir1, Muneeza Ali1, Massimo Di Giannantonio2, Irfan Ullah3, Sheikh Shoib4, Domenico De Berardis2,4,5.   

Abstract

The second year of the COVID-19 (coronavirus disease) pandemic has seen the need to identify and assess the long-term consequences of a SARS-CoV-2 infection on an individual's overall wellbeing, including adequate cognitive functioning. 'Cognitive COVID' is an informal term coined to interchangeably refer to acute changes in cognition during COVID-19 and/or cognitive sequelae with various deficits following the infection. These may manifest as altered levels of consciousness, encephalopathy-like symptoms, delirium, and loss of various memory domains. Dysexecutive syndrome is a peculiar manifestation of 'Cognitive COVID' as well. In the previous major outbreaks of viruses like SARS-CoV, MERS-CoV and Influenza. There have been attempts to understand the underlying mechanisms describing the causality of similar symptoms following SARS-CoV-2 infection. This review, therefore, is attempting to highlight the current understanding of the various direct and indirect mechanisms, focusing on the role of neurotropism of SARS-CoV-2, the general pro-inflammatory state, and the pandemic-associated psychosocial stressors in the causality of 'Cognitive COVID.' Neurotropism is associated with various mechanisms including retrograde neuronal transmission via olfactory pathway, a general hematogenous spread, and the virus using immune cells as vectors. The high amounts of inflammation caused by COVID-19, compounded with potential intubation, are associated with a deleterious effect on the cognition as well. Finally, the pandemic's unique psychosocial impact has raised alarm due to its possible effect on cognition. Furthermore, with surfacing reports of post-COVID-vaccination cognitive impairments after vaccines containing mRNA encoding for spike glycoprotein of SARS-CoV-2, we hypothesize their causality and ways to mitigate the risk. The potential impact on the quality of life of an individual and the fact that even a minor proportion of COVID-19 cases developing cognitive impairment could be a significant burden on already overwhelmed healthcare systems across the world make it vital to gather further evidence regarding the prevalence, presentation, correlations, and causality of these events and reevaluate our approach to accommodate early identification, management, and rehabilitation of patients exhibiting cognitive symptoms.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; brain; cognitive; diagnosis; neurotropism; prevention

Year:  2021        PMID: 34362224     DOI: 10.3390/jcm10153441

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  12 in total

1.  Mild Cognitive Disorder in Post-COVID-19 Syndrome: A Retrospective Cohort Study of 67,000 Primary Care Post-COVID Patients.

Authors:  Jens Bohlken; Kerstin Weber; Steffi Riedel Heller; Bernhard Michalowsky; Karel Kostev
Journal:  J Alzheimers Dis Rep       Date:  2022-06-09

Review 2.  Coronavirus Disease-2019 in Older People with Cognitive Impairment.

Authors:  Yves Rolland; Marion Baziard; Adelaide De Mauleon; Estelle Dubus; Pascal Saidlitz; Maria Eugenia Soto
Journal:  Clin Geriatr Med       Date:  2022-03-21       Impact factor: 3.529

3.  Cognitive deficits and memory impairments after COVID-19 (Covishield) vaccination.

Authors:  Bipin Chaurasia; Vishal Chavda; Bingwei Lu; Kanwaljeet Garg; Nicola Montemurro
Journal:  Brain Behav Immun Health       Date:  2022-04-23

4.  Long-term psychiatric outcomes in youth with enterovirus A71 central nervous system involvement.

Authors:  Hsiang-Yuan Lin; Yi-Lung Chen; Pei-Hsuan Chou; Susan Shur-Fen Gau; Luan-Yin Chang
Journal:  Brain Behav Immun Health       Date:  2022-06-01

5.  First-onset major depression during the COVID-19 pandemic: A predictive machine learning model.

Authors:  Daniela Caldirola; Silvia Daccò; Francesco Cuniberti; Massimiliano Grassi; Alessandra Alciati; Tatiana Torti; Giampaolo Perna
Journal:  J Affect Disord       Date:  2022-04-27       Impact factor: 6.533

Review 6.  Role and Perspectives of Inflammation and C-Reactive Protein (CRP) in Psychosis: An Economic and Widespread Tool for Assessing the Disease.

Authors:  Irfan Ullah; Hashir Ali Awan; Alifiya Aamir; Mufaddal Najmuddin Diwan; Renato de Filippis; Sana Awan; Muhammad Irfan; Michele Fornaro; Antonio Ventriglio; Federica Vellante; Mauro Pettorruso; Giovanni Martinotti; Massimo Di Giannantonio; Domenico De Berardis
Journal:  Int J Mol Sci       Date:  2021-12-02       Impact factor: 5.923

7.  Brain cross-protection against SARS-CoV-2 variants by a lentiviral vaccine in new transgenic mice.

Authors:  Min-Wen Ku; Pierre Authié; Maryline Bourgine; François Anna; Amandine Noirat; Fanny Moncoq; Benjamin Vesin; Fabien Nevo; Jodie Lopez; Philippe Souque; Catherine Blanc; Ingrid Fert; Sébastien Chardenoux; Llta Lafosse; Delphine Cussigh; David Hardy; Kirill Nemirov; Françoise Guinet; Francina Langa Vives; Laleh Majlessi; Pierre Charneau
Journal:  EMBO Mol Med       Date:  2021-10-25       Impact factor: 12.137

8.  Imatinib inhibits SARS-CoV-2 infection by an off-target-mechanism.

Authors:  Romano Strobelt; Julia Adler; Nir Paran; Yfat Yahalom-Ronen; Sharon Melamed; Boaz Politi; Ziv Shulman; Dominik Schmiedel; Yosef Shaul
Journal:  Sci Rep       Date:  2022-04-06       Impact factor: 4.379

9.  Cognitive Dysfunction of Chikungunya Virus Infection in Older Adults.

Authors:  Vanessa Giffoni M N P Peixoto; Julianna P Azevedo; Kleber G Luz; Katie M Almondes
Journal:  Front Psychiatry       Date:  2022-04-05       Impact factor: 5.435

10.  The Frequency and Patterns of Post-COVID-19 Vaccination Syndrome Reveal Initially Mild and Potentially Immunocytopenic Signs in Primarily Young Saudi Women.

Authors:  Kamaleldin B Said; Amal Al-Otaibi; Luluh Aljaloud; Basmah Al-Anazi; Ahmed Alsolami; Fayez Saud Alreshidi
Journal:  Vaccines (Basel)       Date:  2022-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.